Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy
It is very uncertain whether the intervention changes incidence of febrile neutropenia (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of severe infections · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All cause mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 bleeding episode · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).
1 finding from 1 review
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · Patients with treating MF
1 finding from 1 review
Reduction in spleen size Magnetic resonance imaging or computed tomography · Patients with treating MF
Ruxolitinib may leads to higher reduction in spleen size Magnetic resonance imaging or computed… compared with best available therapy (low certainty).
1 finding from 1 review
Overall survival (number of deaths at · Patients with treating MF
Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · Patients with treating MF
Ruxolitinib showed no clear difference in progression Free Survival (number of patients who had progression at compared with best available therapy (low certainty).
1 finding from 1 review